Upadacitinib

WASHINGTON — A drug combining elsubrutinib with upadacitinib led to lower disease activity for up to 104 weeks in patients with moderately to severely active systemic lupus erythematosus, according to data presented at ACR Convergence 2024.

WASHINGTON — Upadacitinib 15 mg is superior to placebo for achieving sustained remission in giant cell arteritis across patient subgroups based on age, sex and glucocorticoid experience, according to data presented at ACR Convergence 2024.

Upadacitinib exhibited efficacy and a favorable benefit-risk profile for the long-term treatment of moderate to severe atopic dermatitis in adolescents, according to a study.

Treatment with 13 mg or 30 mg of upadacitinib showed improvement for patients with atopic dermatitis affecting the head and neck regions, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.